Cargando…
Traumatic submacular hemorrhage: available treatment options and synthesis of the literature
Sub-macular hemorrhage (SMH) is a hematic collection between the neurosensory retina and the retinal pigment epithelium; one of its causes is ocular blunt trauma, that usually affects young patients. Persisting SMH leads to a damage of photoreceptors mediated by three main mechanisms: iron-related t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905055/ https://www.ncbi.nlm.nih.gov/pubmed/31890278 http://dx.doi.org/10.1186/s40942-019-0200-0 |
_version_ | 1783478102046801920 |
---|---|
author | Casini, Giamberto Loiudice, Pasquale Menchini, Martina Sartini, Francesco De Cillà, Stefano Figus, Michele Nardi, Marco |
author_facet | Casini, Giamberto Loiudice, Pasquale Menchini, Martina Sartini, Francesco De Cillà, Stefano Figus, Michele Nardi, Marco |
author_sort | Casini, Giamberto |
collection | PubMed |
description | Sub-macular hemorrhage (SMH) is a hematic collection between the neurosensory retina and the retinal pigment epithelium; one of its causes is ocular blunt trauma, that usually affects young patients. Persisting SMH leads to a damage of photoreceptors mediated by three main mechanisms: iron-related toxicity, impairment of diffusion of oxygen and nutriment, mechanical damage due to clot contraction. Since early photoreceptors’ damage has been reported within 24 h, it is suggested to provide an early treatment, although there are no guidelines or consensus between authors regarding treatment strategies. The aim of this review was to present and compare available treatment options, like intravitreal tissue plasminogen activator (tPA) associated with pneumatic displacement, pneumatic displacement alone, subretinal tPA injection with pneumatic displacement, and intravitreal anti-vascular endothelial growth factor (VEGF) injection. All procedures obtained consistent results, though the most effective seemed to be pars plana vitrectomy, subretinal tPA and gas tamponade, probably due to a quicker liquefaction and displacement of the clot. Limitations concern the greater invasiveness and the higher incidence of complications. Alternatively, intravitreal injection of tPA and gas may represent a less invasive option with fewer complications. Intravitreal injection of gas and prone position could be preferred in young patients without coexisting ocular pathology, being a minimally invasive treatment, with lower risk of complications and a good visual recovery. Anti-VEGF agent have found, to date, limited employment in cases of traumatic SMH even though they may be useful as alternative or adjuvant therapy. Most of the published literature consists of small studies and case reports, therefore further investigations and larger clinical trials are required to fully understand safety and efficacy of the procedures. A preoperative comprehensive evaluation may be helpful to realize a surgical plan tailored on patient. |
format | Online Article Text |
id | pubmed-6905055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69050552019-12-30 Traumatic submacular hemorrhage: available treatment options and synthesis of the literature Casini, Giamberto Loiudice, Pasquale Menchini, Martina Sartini, Francesco De Cillà, Stefano Figus, Michele Nardi, Marco Int J Retina Vitreous Review Sub-macular hemorrhage (SMH) is a hematic collection between the neurosensory retina and the retinal pigment epithelium; one of its causes is ocular blunt trauma, that usually affects young patients. Persisting SMH leads to a damage of photoreceptors mediated by three main mechanisms: iron-related toxicity, impairment of diffusion of oxygen and nutriment, mechanical damage due to clot contraction. Since early photoreceptors’ damage has been reported within 24 h, it is suggested to provide an early treatment, although there are no guidelines or consensus between authors regarding treatment strategies. The aim of this review was to present and compare available treatment options, like intravitreal tissue plasminogen activator (tPA) associated with pneumatic displacement, pneumatic displacement alone, subretinal tPA injection with pneumatic displacement, and intravitreal anti-vascular endothelial growth factor (VEGF) injection. All procedures obtained consistent results, though the most effective seemed to be pars plana vitrectomy, subretinal tPA and gas tamponade, probably due to a quicker liquefaction and displacement of the clot. Limitations concern the greater invasiveness and the higher incidence of complications. Alternatively, intravitreal injection of tPA and gas may represent a less invasive option with fewer complications. Intravitreal injection of gas and prone position could be preferred in young patients without coexisting ocular pathology, being a minimally invasive treatment, with lower risk of complications and a good visual recovery. Anti-VEGF agent have found, to date, limited employment in cases of traumatic SMH even though they may be useful as alternative or adjuvant therapy. Most of the published literature consists of small studies and case reports, therefore further investigations and larger clinical trials are required to fully understand safety and efficacy of the procedures. A preoperative comprehensive evaluation may be helpful to realize a surgical plan tailored on patient. BioMed Central 2019-12-11 /pmc/articles/PMC6905055/ /pubmed/31890278 http://dx.doi.org/10.1186/s40942-019-0200-0 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Casini, Giamberto Loiudice, Pasquale Menchini, Martina Sartini, Francesco De Cillà, Stefano Figus, Michele Nardi, Marco Traumatic submacular hemorrhage: available treatment options and synthesis of the literature |
title | Traumatic submacular hemorrhage: available treatment options and synthesis of the literature |
title_full | Traumatic submacular hemorrhage: available treatment options and synthesis of the literature |
title_fullStr | Traumatic submacular hemorrhage: available treatment options and synthesis of the literature |
title_full_unstemmed | Traumatic submacular hemorrhage: available treatment options and synthesis of the literature |
title_short | Traumatic submacular hemorrhage: available treatment options and synthesis of the literature |
title_sort | traumatic submacular hemorrhage: available treatment options and synthesis of the literature |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905055/ https://www.ncbi.nlm.nih.gov/pubmed/31890278 http://dx.doi.org/10.1186/s40942-019-0200-0 |
work_keys_str_mv | AT casinigiamberto traumaticsubmacularhemorrhageavailabletreatmentoptionsandsynthesisoftheliterature AT loiudicepasquale traumaticsubmacularhemorrhageavailabletreatmentoptionsandsynthesisoftheliterature AT menchinimartina traumaticsubmacularhemorrhageavailabletreatmentoptionsandsynthesisoftheliterature AT sartinifrancesco traumaticsubmacularhemorrhageavailabletreatmentoptionsandsynthesisoftheliterature AT decillastefano traumaticsubmacularhemorrhageavailabletreatmentoptionsandsynthesisoftheliterature AT figusmichele traumaticsubmacularhemorrhageavailabletreatmentoptionsandsynthesisoftheliterature AT nardimarco traumaticsubmacularhemorrhageavailabletreatmentoptionsandsynthesisoftheliterature |